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Abstract
Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of molecules
associated with one of the major pathways through which many cytokines exert and integrate their func-
tion, and as such they are increasingly recognized as playing critical role in the pathogenesis subserving
various immune-mediated diseases, including RA, PsA, SpAs, IBD, skin disorders (e.g. alopecia areata,
atopic dermatitis), single-gene disorders like interferonopathies, and others. JAKs are the key initiating
players of the JAK/STAT pathway. Upon binding of their respective effector molecules (cytokines, IFNs,
growth factors and others) to type I and type II receptors, JAKs are activated, and through phosphoryl-
ation of themselves and of other molecules (including STATs), they mediate signal transduction to the
nucleus. A class of drugs—called JAK inhibitors or JAKinibs—that block one or more JAKs has been
developed in the last decade, and now numbers >20 members. Although, so far, JAK inhibitors have been
marketed only for RA and PsA, these drugs have been tested in phase 2 and phase 3 clinical trials for
other inflammatory conditions and beyond. In this review, we summarize the clinical data, including effi-
cacy and safety, available for JAK inhibitors used in some immune-mediated conditions other than RA.
Key words: JAK/STAT pathway, JAK inhibitors, immune-mediated diseases
Rheumatology key messages
. Janus kinase inhibitors are increasingly being tested for inflammatory diseases other than RA.
. The value of different Janus kinase inhibitors’ specificities across disease states remains to be defined.
. The acceptable safety profile of Janus kinase inhibitors, across disease states, remains to be confirmed.
Introduction
In recent years, advances in the field of basic and trans-
lational research have identified pathways and molecular
targets at the subcellular level that regulate immune re-
sponses, leading in turn to the development of many new
drugs.
One of these is the Janus kinase (JAK)/signal trans-
ducers and activators of transcription (STAT) pathway,
which appears to have a pivotal role in the pathogenesis
of many immune-mediated diseases, by facilitating the
signal transduction of many different cytokines and other
molecules [1]. During the last decade, drugs known as
JAK inhibitors or JAKinibs, blocking one or more of the
molecules involved in this pathway, have been developed
and tested in clinical trials for many different indications.
Although the focus of JAK inhibitors for the treatment of
chronic inflammatory conditions has been on RA, there
are other conditions in which JAKinibs could serve as
therapeutic options [2]. Herein, we describe the immune-
mediated rheumatological indications—other than
RA—for which JAK inhibitors have been approved or
tested in clinical trials. We also present the basic prin-
ciples of their mode of action and the consequent safety
concerns raised.
The JAK/STAT pathway
JAKs, named after the two-faced Roman God Janus, form
a family consisting of four members: JAK1, JAK2, JAK3
and TYK2. They are all cytoplasmic tyrosine kinases able
to phosphorylate tyrosine residues either on themselves
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(autophosphorylation) or on adjacent molecules (trans-
phosphorylation), including the STATs. The latter is a
family of transcription factors, acting downstream of
JAKs and consisting of 7 members [3]. The JAK/STAT
pathway is an evolutionarily conserved pathway mediating
the effect of many different molecules, including ILs, IFNs,
colony-stimulating factors, growth factors and hormones
(also known as hormone-like cytokines), which exert their
function through type I and type II receptors [3] (Fig. 1).
Type I receptors are used by several ILs, colony-stimulat-
ing factors and hormones, while type II receptors are used
by IFNs and IL-10related cytokines (IL-10, IL-19, IL-20,
IL-22, IL-22 and IL-26) [3]. These receptors consist of vari-
ous subunits, each of them associated with a JAK mol-
ecule. Upon ligation of the effector protein with its
receptor, the latter is oligomerized, leading to activation
of the relevant JAK, which, in turn, is autophosphorylated
and also transfers a phosphate to a tyrosine residue in the
receptor’s subunit, creating a docking site for a STAT mol-
ecule. The STAT molecule is also phopsphorylated by the
JAK. Subsequently, STATs are dimerized and translocate
from cytosol to the nucleus, thereby regulating gene ex-
pression [2].
Receptor subunits are associated with a specific JAK;
some of them may be associated with more than one JAK.
Also, as the JAK family has only four members, many dif-
ferent cytokines may act through the same JAK.
Consequently, inhibiting a JAK molecule may impede
more than one pathway, which may in part explain both
the efficacy obtained and some of the adverse effects
observed with JAK inhibitor treatment [4].
Many JAKinibs have been developed over recent years
(Table 1), often subcategorized as first-generation and
newer JAKinibs. The first-generation JAKinibs do not dis-
play high specificity, demonstrating activity against three
or even all four of the JAK family members (also termed as
pan-JAK inhibitors). Selectivity against specific JAKs is a
desirable feature of the newer JAKinibs, primarily in terms
of mitigating side effects. Currently only two JAKinibs
have approval for the treatment of RA and PsA.
However, these and other JAK inhibitors appear to also
have a potential position in the treatment of many other
autoimmune diseases, including: SpAs; psoriasis and
other skin diseases such as atopic dermatitis (AD) and
alopecia areata (AA); IBD; uveitis; GCA; and single-gene
disorders, such as the so-called interferonopathies.
PsA and SpAs
The potential mode of action of JAKinibs in psoriatic dis-
ease is not fully understood. However, there are data from
animal models and ex vivo experiments suggesting that
the JAK/STAT pathway is linked to the IL-23/-17 axis,
which in turn plays a crucial role in the underlying patho-
genesis of PsA and spondyloarthropathies. Although IL-17
per se does not seem to employ the JAK/STAT pathway
[5], IL-23 (which is an upstream driver of IL-17A release)
exerts it’s function through the JAK2-TYK2/STAT3-STAT4
system [4, 6, 7]. Additionally, IL-22 (also a key player in the
pathogenesis of SpAs and an important mediator of the
IL-23/-17 axis) uses the JAK/STAT pathway [4, 6]. Finally,
type I IFNs are also implicated in some elements of the
PsA articular and cutaneous response.
In animal arthritis models, JAKinibs have been found to
inhibit, dependent on the cytokine environment, the
expression of Th17-related cytokines (IL-17A, IL-17F,
IL-22), thereby blocking the IL-23/-17 axis [8]. Ex vivo stu-
dies have shown that in synovial fluid samples obtained
from patients with PsA, proteins involved in (or functionally
related to) the JAK/STAT pathway [JAK1, Extracellular
signal-Regulated Kinase (ERK) 1/2, STAT1, STAT3,
STAT5] are increased [9]. The coculture of synovial fibro-
blasts derived from PsA patients or PsA synovial explants
with tofacitinib (a first-generation JAK3/1 inhibitor with
less activity for JAK2 and possibly TYK2) led to reduced
expression of phosphoproteins involved in the pathway,
decreased ability of fibroblasts to form networks and mi-
grate, and decreased secretion of inflammatory cytokines
and effector proteins, such as metalloproteinases [10].
Additionally, a recently published study demonstrated
that tofacitinib inhibited phosphorylation of JAK2 and
STAT3 induced by IL-23 in peripheral blood mononuclear
cells from PsA patients, and hindered proliferation of
CD4+CD11+CD45RO+IL-17+ T cells (also known as IL-
17+ effector memory cells) in peripheral blood mononu-
clear cells and mononuclear synovial fluid cells from PsA
patients [7, 11]. These findings suggest a link between
FIG. 1 Schematic representation of the various cytokines and their receptors signalling via the JAK/STAT
signal-transduction pathway
EPO: erythropoietin; TPO: thrombopoietin; JAK: Janus kinase; TYK: tyrosine kinase; P: phosphorus; STAT: signal
transducer and activation of transcription.
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JAKinibs and the IL-23/-17 axis and therefore partially ex-
plain the effectiveness of this drug class in PsA and SpAs.
A recent clinical research programme led to the Food
and Drug Administration approving tofacitinib for PsA. The
results from large phase 3 trials have recently been pub-
lished. In summary, a placebo and adalimumab con-
trolled, 12-month, double-blind study demonstrated that
tofacitinib in doses of 5 mg bd (twice a day) or 10 mg bd
was superior to placebo in active PsA patients who were
non-responders to conventional DMARDs. Significantly
more patients treated with tofacitinib achieved the primary
end points [ACR20 and changes in HAQ score] at week
12, compared with placebo; (ACR20 response rates; tofa-
citinib 5 mg: 50%; tofacitinib 10 mg: 61%; versus placebo:
33%, P= 0.01 and P< 0.001, respectively). Significant dif-
ferences in the ACR20 rates were already observed from
week 2. Most of the secondary end points (including at
least 75% improvement in Psoriasis Area and Severity
Index (PASI75) score, ACR50 and ACR70) were also
achieved, at week 12, in significantly higher rates in both
groups treated with tofacitinib versus placebo. A signifi-
cantly greater decrease in the Leeds enthesitis index was
observed for the 10 mg-treated, but not for the 5 mg-
treated group versus placebo. The results were main-
tained until month 12. Although not designed specifically
for this purpose, both tofacitinib-treated groups showed
similar efficacy to the adalimumab group. Finally, at
month 12, >90% of the patients across all groups met
the criteria for radiographic non-progression in the
joints. [12] In a linked study reported in the same journal,
PsA patients with inadequate response to biologic drugs
were randomized to receive tofacitinib 5 mg bd or 10 mg
bd, or placebo [13]. At week 12, patients who received the
active drug achieved the primary end point (ACR20 and
changes in HAQ scores) in statistically significantly higher
percentages (ACR20 response rates tofacitinib 5 mg:
50%; tofacitinib 10 mg: 47%) and most of the secondary
end points (ACR50, PASI75—the difference in PASI75
was not statistically significant for tofacitinib 5 mg bd)
compared with those who received placebo
(ACR20: 24%). The results were maintained until month
6 [13]. Phase 2 and phase 3 clinical trials are underway
to assess the efficacy and safety of other, next
generation JAKinibs like the JAK1 inhibitors filgotinib
(ClinicalTrials.gov— NCT03101670, NCT03320876)
and upadacitinib (ClinicalTrials.gov—NCT03104374,
NCT03104400) in PsA.
The promising results of JAKinibs in the field of inflam-
matory arthritis and the fact that polymorphisms in JAK2
and STAT3 have been associated with susceptibility to
AS [14, 15] paved the way for the investigation of these
reagents as treatments for AS. Favourable results have
recently been published from a phase 2, placebo-con-
trolled, dose-ranging study, in which AS patients were
randomized to one of three doses (2 mg, 5 mg, 10 mg; all
bd) of tofacitinib [16]. Patients on 5 mg bd achieved the
primary end point [ASAS20 (Assessment in AS 20% im-
provement)] at week 12, at significantly higher rates com-
pared with placebo (tofacitinib 5 mg: 80.8%; placebo:
41.2%, P< 0.001). At the same time point, patients at all
doses of tofacitinib achieved most of the secondary end
points, including ASAS40 (ASAS 40% improvement),
BASDAI50 (BASDAI 50% improvement), improvement
at Spondyloarthritis Research Consortium of Canada
(SPARCC) spine scores and quality of life indices.
Furthermore, the 5 mg bd and 10 mg bd groups demon-
strated significant differences at week 12, compared with
placebo, in SI joint SPARCC scores and in enthesitis, as
assessed by the change from baseline in the Maastricht
AS Enthesitis Score index. In a post hoc analysis of this
study, with a focus on the magnetic resonance imaging
findings in these patients [17], it was shown that Minimally
Important Changes for SPARCC spine and SPARCC SI
joints scores were achieved in approximately one-third
of the patients treated with tofacitinib. A greater propor-
tion of patients who achieved Minimally Important
Changes, compared with those who did not, achieved
clinically meaningful responses, like ASAS20 and
ASAS40. Phase 2 studies are underway evaluating the
efficacy and safety of filgotinib and upadacitinib in AS
(NCT03117270, NCT03178487, respectively).
Psoriasis
Psoriasis is another condition for which JAK inhibitors
appear to be a very promising therapeutic option. In es-
sence, the rationale for their use maps to that laid out for
PsA and AS. Thus, many of the molecules with an active
role in the pathogenesis of psoriasis, like IL-23, IL-22,
IL-15 and IFNg [1820], employ the JAK/STAT pathway
to mediate their function.
Phase 2 trials, assessing the safety and efficacy of tofa-
citinib in patients with psoriasis, carried out after promis-
ing results from phase 1 studies [21], showed clinical
improvement in psoriasis, as assessed by the PASI75 re-
sponse at week 12 [22, 23]. Quality of life indices were
also improved by tofacitinib [22].
Phase 3 trials confirmed these early phase results. In
two large studies (OPT Pivotal 1 and OPT Pivotal 2), with
similar protocols, it was demonstrated that psoriasis pa-
tients who received tofacitinib (5 mg or 10 mg, both bd),
achieved PASI75 at week 16 in higher percentages (OPT
Pivotal 1, 5 mg: 39.9%; 10 mg: 59.2% and OPT Pivotal 2,
5 mg: 46.0%; 10 mg: 59.6%), compared with those
received placebo (OPT Pivotal 1: 6.2%; OPT Pivotal 2:
11.4%) [24]. The results were maintained until month 24
[25]. Improvement in nail psoriasis, as assessed by the
Nail Psoriasis Severity Index score, was also observed
at week 16 and generally maintained until week 52 [26].
Additionally, a separate phase 3, 12-week trial, examined
the noninferiority of tofacitinib versus etanercept, having
as co-primary end points the proportion of patients
achieving PASI75 and Physician Global Assessment
scores of ‘clear’ or ‘almost clear’. Patients with stable
psoriasis were randomized to receive tofacitinib 5 mg
bd, tofacitinib 10 mg bd, etanercept 50 mg twice weekly,
or placebo. The results showed that tofacitinib 10 mg bd,
but not 5 mg bd, was superior to placebo and not inferior
to etanercept at week 12, as assessed by the percentage
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of patients achieving the PASI75 response (5 mg: 39.5%;
10 mg: 63.6%, etanercept: 58.8; placebo: 5.6%) and the
Physician Global Assessment scores [27]. In a linked
study [28], patient-reported outcomes were significantly
improved for tofacitinib- and etanercept-treated patients
versus placebo. In summary, by week 12, all active groups
achieved a Dermatology Life Quality Index score of 0 or 1
in significantly higher percentages compared with pla-
cebo (P< 0.0001, for all comparisons). Also, the propor-
tion of patients with a patient’s global assessment for
psoriasis score of 0 or 1, from week 4 and onwards,
was significantly higher for all active-treatment groups,
compared with placebo (P< 0.0001, for all comparisons).
Finally, itchiness [measured by Itch Severity Item] was
also significantly improved, already from day 1 in both
tofacitinib-treated groups versus placebo (P< 0.05, for
both). The 10 mg-tofacitinib-treated group achieved an
Itch Severity Item score of 0 or 1 in a greater percentage
of patients compared with etanercept, from week 2 up to
week 12 (P< 0.05 for all comparisons). Another phase 3
trial showed that treatment withdrawal of tofacitinib led to
flare of psoriasis in more than half of the cases.
Retreatment recovered efficacy in 60% of the patients.
The reason for that is currently unknown. Development of
anti-drug antibodies has been suggested to explain simi-
lar phenomena occurring in patients treated with mono-
clonal antibodies. However, this mechanism does not
apply for treatment with tofacitinib, given that it is a
small molecule and thus non-immunogenic [29]. Topical
application of tofacitinib ointment (2%) for psoriasis has
also been tested in a phase 2 trial and was found superior
to placebo at week 8, but not at week 12 [30].
Baricitinib (a JAK1/2 inhibitor) was tested in a phase 2
trial in psoriasis. Patients who received 8 mg or 10 mg per
day achieved significantly higher PASI75 response rates
at week 12, compared with placebo [31]. The majority of
the responders maintained their scores through week 24
[31]. In another phase 2 trial, peficitinib (a pan-JAK inhibi-
tor with moderate selectivity for JAK3 over the other
JAKs), orally administrated, demonstrated dose-depend-
ent clinical and histological improvement versus placebo
at week 6 [32]. Treatment with the selective JAK1 inhibi-
tors PF-04965842 and Solcitinib (GSK2586184) in phase 2
trials, was also found to be more effective than placebo at
weeks 4 and 12, respectively [33, 34].
Topical application of ruxolitinib (a JAK1/2 inhibitor
approved for the treatment of myeloproliferative diseases)
in patients with psoriasis, resulted in clinical improvement
and downregulation of transcriptional markers of immune
activation in lesional skin [35]. Decreased dermal inflam-
mation and epidermal hyperplasia was also observed
[35, 36]. Phase 2 trials are ongoing for topical ruxolitinib
treatment in patients with plaque psoriasis (NCT00617994,
NCT007787700).
Phase 2 trials are also underway evaluating the safety
and efficacy of various other JAKinibs (like INCB039110-
itacitinib) in patients with plaque psoriasis (NCT01634087).
Other skin diseases
Apart from psoriasis, JAK inhibitors also seem to be ef-
fective for some other skin diseases; often their pathogen-
esis implicates IFN and ILs acting through type-I cytokine
receptors as important mediators. In AA animal models, it
was shown that IL-2, IL-15 and IFN-g play a significant
role in the pathogenesis [37]. Given that they all act
through the JAK/STAT pathway, it was reasonable to hy-
pothesize that JAK inhibitors would be promising thera-
peutic agents. Indeed, initial small studies indicated that
treatment with ruxolitinib led to decreased perifollicular
infiltration of T cells, normalization of inflammatory signa-
tures and clinical improvement with hair regrowth after
35 months of systemic treatment [38]. Two small, open
label-studies assessing the efficacy of tofacitinib were re-
cently published. The first one demonstrated that in pa-
tients with AA and its variants, alopecia totalis and
alopecia universalis, 3-month treatment with tofacitinib
led to significant improvement in approximately two-
thirds of the patients [39]. However, the disease flared-up
when treatment was discontinued. A smaller, open-label,
study and a retrospective study also reported that tofaci-
tinib was efficacious for the treatment of AA and its vari-
ants [40, 41]. Of note, tofacitinib appears to also be helpful
for the treatment of nail dystrophy in the context of AA
[42]. Topical treatment with tofacitinib had less impressive
results compared with oral administration, helping ap-
proximately 30% of the patients in a small, open-label
study [43]. These results have also been replicated in an
adolescent population [44]. A phase 2 clinical trial of
topical tofacitinib for AA is ongoing (NCT02812342).
Promising results were also obtained from a pilot, open-
label study, in which patients with moderate to severe AA
were treated with oral ruxolitinib. At month 6, the vast
majority of the patients (75%) displayed significant im-
provement [45]. Topical treatment with ruxolitinib has
also been reported in case reports with conflicting results
[46, 47]. A phase 2 trial was recently completed, but no
results have been published yet (NCT02553330).
AD is another skin disease for which JAKinibs could serve
as an attractive treatment modality. Th2 cells are thought to
be the hierarchical driving cells in the pathogenesis of AD,
interacting with altered skin barrier function. IL-4, acting
through its receptor, which is associated with JAK1/JAK3, is
the main cytokine implicated in AD, through promoting and
inhibiting differentiation of Th2 cells and keratinocytes, re-
spectively [48, 49]. Tofacitinib has been tried as a systemic
treatment for AD in a small study with good results [50], while
a phase 2, placebo-controlled study has also been published,
indicating that AD patients treated with topical applications of
tofacitinib experienced significant improvement at week 4,
with favourable results being evident from week 1 [51]. A re-
cently published study, reported that baricitinib was better
than placebo at week 16 for AD treatment [52]. In addition,
there are ongoing phase 2 and phase 3 trials assessing the
safety and efficacy of topical ruxolitinib (NCT 03011892) and
systemic administration of PF-04965842 (NCT03349060,
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NCT03422822), baricitinib (NCT 03428100, NCT 03435081,
NCT 03334435, NCT03334422, NCT 03334396) and upada-
citinib (NCT 02925117) in AD.
JAKinibs have also been examined as potential treat-
ment for vitiligo, given the central role of IFN-g in its patho-
genesis [53]. Both tofacitinib and ruxolitinib have been
tested with good results, although the disease relapses
after treatment discontinuation [54, 55]. A small proof-of-
concept study for topical ruxolitinib yielded promising re-
sults, especially for facial vitiligo [56]. Another phase 2
clinical trial of local treatment with ruxolitinib is currently
underway (NCT02809976).
IBD
Genome-wide association and other studies have shown as-
sociation between genetic variants in JAK2, STAT3, TYK2
genes, and IL-23 receptor gene and Crohn’s disease (CD)
[5759]. Also, various cytokines, including IL-12, IL-23, IL-21,
IL-22, IL-27 and IFN-g, have been identified as playing a key
role in the pathogenesis of CD. These molecules exert their
action via the JAKSTAT pathway, involving all members of
the JAK family, making thus, JAKininbs an attractive treat-
ment option for CD [6, 57, 60]. However, results for tofacitinib
in CD were not encouraging, as no difference was seen in
clinical response or clinical remission for various doses,
versus placebo [61, 62]. In contrast, filgotinib and upadaciti-
nib reported favourable results in phase 2 studies, perhaps
reflecting the close regulatory inflammatory cross talk in
leucocyte subsets (e.g. Treg vs Tresponder) within the
gastrointestinal mucosa and their differential sensitivity to
discrete JAK pathway inhibition, especially of JAK1, while
sparing JAK3. In summary, patients with moderate to
severe CD were randomized to treatment with filgotinib or
placebo [63]. At week 10, significantly more patients in the
active-drug arm compared with placebo achieved clinical
remission [Crohn’s disease activity index (CDAI)< 150] and
clinical response (drop of CDAI of >100) [63]. Phase 3 trials
are ongoing to evaluate filgotinib as induction or mainten-
ance treatment in CD (NCT02914561, NCT02914600). In an-
other study, patients with moderate to severe CD refractory
to treatment with TNF inhibitors were treated with various
doses of upadacitinib or placebo. At week 16, compared
with placebo, significantly more patients on 6 mg upadaciti-
nib twice a day, achieved clinical remission, and all patients
receiving doses56 mg achieved endoscopic response [64].
Several phase 2 and phase 3 studies are ongoing to evaluate
the efficacy and safety of the drug as induction therapy in
patients with CD resistant to conventional or biologic treat-
ments, and also to assess its feasibility as maintenance treat-
ment for CD (NCT03345836, NCT03345849, NCT03345823,
NCT02365649, NCT02782663).
As regards ulcerative colitis (UC), tofacitinib appears to
be a promising therapeutic [61]. In a phase 2, placebo-
controlled trial, patients with moderate to severe UC were
randomized to receive various doses of tofacitinib.
Patients who received 15 mg bd achieved clinical re-
sponse at week 8 at a significantly higher rate compared
with placebo. Clinical remission (defined as a Mayo score
42 with no subscore >1) was also achieved at week 8 by
patients receiving 3 mg bd or higher doses of tofacitinib
[65]. Subsequently, three phase 3 trials (OCTAVE pro-
gramme) reported that more patients with moderate to
severe UC who had failed conventional or biologic therapy
but were treated with 10 mg bd of tofacitinib achieved
higher rates of clinical remission, clinical response and
mucosal healing at week 8, compared with placebo [66].
In addition, it was shown that remission occurred more
frequently at week 54 in patients who received tofacitinib
5 mg or 10 mg bd as a maintenance treatment for UC,
compared with placebo [66]. Furthermore, quality of life
indices were significantly improved in patients treated
with tofacitinib, evident from week 8, and the difference
was maintained until week 54 [67].
A phase 2 trial evaluating peficitinib (also known as
JNJ-54781532) has been completed, but the results are
not yet available (NCT01959282), and phase 3 trials assess-
ing the safety and efficacy of upadacitinib (NCT03006068,
NCT02819635) and filgotinib (NCT02914535, NCT02914522)
as induction or maintenance treatment for UC are currently
underway.
Single-gene disorders (interferonopathies)
Type I interferonopathies are a heterogeneous group of auto-
inflammatory disorders incorporating phenotypically different
diseases like AicardiGoutie`res syndrome, chilblain lupus,
Stimulator of interferon genesAssociated Vasculopathy
with onset in Infancy (SAVI), SingletonMerten syndrome,
retinal vasculopathy with cerebral leukodystrophy, Chronic
Atypical Neutrophilic Dermatosis with Lipodystrophy and
Elevated Temperature (CANDLE) and others [68]. In these
disorders, genes involved in the IFN-I signalling pathway
are aberrantly expressed, leading to its upregulation. In the
canonical IFN-I pathway, IFN-I binds to the IFN-I recep-
tor—constituted by two chains: IFN-I receptor 1 and IFN-I
receptor 2—which activates JAK1 and TYK2. Subsequently,
STAT1 and STAT2 are phosphorylated and activate IFN
Type-Istimulated genes [69]. Therefore, it has been sug-
gested that JAK inhibition could be a reasonable approach
in the treatment of these disorders.
There are some initial promising results. SAVI is a re-
cently described interferonopathy associated with gain-
of-function mutations in TMEM173 encoding stimulator
for interferon genes [70]. Ruxolitinib appears to be a
therapeutic option for these patients. In a case-series
report, three SAVI patients treated with ruxolitinib ex-
hibited significant symptomatic improvement, accompa-
nied by a decrease in IFN-stimulated genes in two
patients [71]. Similarly, two patients from a family with
chilblain lupus associated with mutated stimulator of
interferon genes treated with tofacitinib 5 mg bd dis-
played clinical improvement, along with suppression of
the IFN signature [72], while a another case study re-
ported a patient with the same disease successfully trea-
ted with ruxolitinib [73]. Ruxolitinib has also been used in
patients with AicardiGoutie`res syndrome with good re-
sponse [74]. Also, in 2011, the Food and Drug
Administrationapproved compassionate programme
(NCT01724580) was initiated. In this program, patients
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with CANDLE or SAVI were included, to receive treat-
ment with baricitinib [75]. The optimal dosing of
JAKinibs in interferonopathies is still to be resolved, as
the pharmacodynamics may be affected by renal func-
tion and weight [75].
Eye diseases
In an experimental autoimmune uveitis model, topical
treatment with tofacitinib (0.03%) three times a day was
found to improve uveitis, clinically and histologically, and
to reduce the intravitreous levels of inflammatory cyto-
kines and their gene expression in both the irisciliary
body and the retina/choroid [76, 77]. A phase 2 clinical
trial is underway assessing the efficacy and safety of
orally administrated filgotinib in patients with non-infec-
tious uveitis (NCT03207815).
GCA
Recent studies support the notion that JAK inhibitors
could be potentially efficacious in patients with GCA. In
a chimeric model, where vascular inflammation was
induced in human vessels engrafted to immunodeficient
mice, treatment with tofacitinib reduced proliferation rates
of lesional T cells and the production of IFN-g, IL-17 and
IL-21 [78]. Micro-angiogenesis, outgrowth of the intima
and the number of the CD4+CD103+ T memory cells
were also reduced [78]. A phase 2 study, testing the
safety and efficacy of baricitinib in relapsing GCA, is
underway (NCT03026504).
Safety of JAKinibs
To date, the safety profile of JAKinibs appears to be ac-
ceptable and comparable with those of biologic drugs
used for the treatment of immune-mediated diseases.
Most of the safety data come from the large trials of tofa-
citinib in RA, while evidence for other JAKinibs continues
to accumulate. At this time, therefore, much of the safety
inference must come from the large RA cohorts—it is not
yet clear whether other diseases will bring with them novel
adverse event profiles. As summarized in a recently pub-
lished analysis using data from phase 13 trials and long-
term extension studies for RA patients treated with
tofacitinib, the incidence rate for severe infections has
been estimated to be 2.7 per 100 patient-years, which
is on par with those for biologics currently used in clinical
practice for the treatment of RA [79]. While it appears that
tofacitinib is associated with a higher risk of herpes zoster
infection compared with biologics, this is usually mild and
limited to a single dermatotome [80]. Herpes zoster infec-
tion with tofacitinib was more common in Asia and in
people who were on concomitant glucocorticosteroids
at baseline [79]. The frequency of malignancies (other
than non-melanoma skin cancer) remained stable over
time, despite increased exposure to tofacitinib, and was
within the same range observed for RA treated with bio-
logics [81].
Cardiovascular risk was one of the concerns raised
about JAKinibs, largely related to the alterations in lipid
profile noted with this class of drugs. Long-term data are
reassuring thus far. In RA patients treated with tofacitinib,
lipids were generally increased in the first 3 months of
treatment, but stabilized thereafter [82]. This alteration
was not associated with an increase in major adverse car-
diovascular events, the incidence rates of which were
comparable to those for placebo in the clinical trials and
not increased in long-term extension studies [82].
Furthermore, the low-density lipoprotein (LDL): high-dens-
ity lipoprotein (HDL) ratio remained generally stable after
24 months [79, 82]. In psoriasis patients, it seems that
while there are increases in the total cholesterol, LDL
and HDL levels, the total cholesterol : HDL ratio remains
stable, the number of the more atherogenic small dense
LDL particles does not change [83] and the incidence
rates of major adverse cardiovascular events remains
low [84]. Long-term data will, however, be required to re-
assure and inform use in patients already at a high base-
line risk of cardiovascular events.
The data for tuberculosis (TB) are limited and are again
obtained largely from tofacitinib studies [85]. Of patients
with latent TB treated with isoniazid prophylaxis, there are
no reported cases of active TB. As with biologic drugs, the
frequency of TB was found to be increased in geograph-
ical regions with high background TB prevalence.
The data so far do not allow sufficient risk comparison
for TB between the various biologics and JAKinibs.
Laboratory abnormalities seen during treatment with
tofacitinib include decreases in the numbers of neutro-
phils, lymphocytes, NK cells and platelets, as well as
increased transaminases and serum creatinine levels.
However, these alterations are usually mild and reversible
[86]. Haemoglobin levels may be found to be increased.
Pooled data from phase 3 and long-term extension stu-
dies showed that haemoglobin levels were initially
increased and then were stabilized for up to 66 months
of treatment with tofacitinib. Additionally, an inverse asso-
ciation was observed between increase in haemoglobin
and disease activity, as assessed by ESR and CRP.
Thus, it seems that reduction in systemic inflammation
counterbalances the minor negative effects of tofacitinib
in erythropoiesis. In addition, tofacitinib is a JAK3/JAK1
inhibitor with a limited effect on JAK2, which is used by
erythropoietin [87]. The baricitinib trials in RA indicate that
it has a similar safety profile to that of tofacitinib, although
laboratory aberrancies might be slightly different, with
more stable lymphocyte and platelet counts and a greater
decrease in haemoglobin levels [86]. The latter could be
explained by an inhibitory effect of baricitinib on JAK2.
However, data obtained from phase 2, phase 3 and on-
going open-label extension studies suggest that reduction
in haemoglobin levels is dose-dependent, being more
pronounced in patients treated with 8 mg of baricitinib
once daily, and only rarely being clinically significant
or leading to treatment discontinuation [8890].
Furthermore, it seems that counteracting mechanisms di-
minish this reduction in haemoglobin levels, over time [88].
Small decreases in neutrophil levels and increases in
serum creatinine have been observed [89, 91]. Increases
in LDL and HDL levels are stabilized after 3 months of
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treatment, and the LDL: HDL cholesterol ratio remains
stable [92]. The risk of herpes zoster infection with barici-
tinib appears to be comparable with that observed for
tofacitinib [86], although a recent study suggests that
this might be lower [89].
For other JAKinibs, data are less robust and further
studies are needed to define their safety profile. Data for
peficitinib are very limited, but it seems that the data are
largely similar to those for tofacitinib [93, 94]. Interestingly,
the side-effect profile for decernotinib appears compar-
able with those observed for other JAKinibs, despite
decernotinib being a selective JAK3 inhibitor, which
might therefore be predicted to have fewer off-target
side effects [9597]. Furthermore, as a potent CYP3A4
inhibitor, with potential to affect the metabolism of many
other drugs, serious concerns have been raised [1, 98].
A developmental program for solcitinib, a selective JAK1
inhibitor, has been discontinued because of severe side
effects, including serious but reversible derangement of
liver function tests and adverse reactions [Drug Reaction
with Eosinophilia and Systemic Symptoms (DRESS) syn-
drome] to the drug [99].
Safety data for upadacitinib appear similar to those for
tofacitinib, although haemoglobin was found to be
decreased with high doses [100, 101]. The early data sug-
gest that filgotinib appears to have a slightly different
safety profile in relation to the laboratory abnormalities.
No increase in liver function tests or decrease in haemo-
globin levels or number of lymphocytes or NK cells was
observed in the trials conducted for RA patients
[102, 103]. Additionally, despite the fact that both LDL
and HDL were increased during treatment with filgotinib,
the LDL:HDL ratio fell [102, 104]. Further studies are
needed to confirm these findings. The degree of class
effect and drug specificity relating to adverse events of
JAKinibs remains to be determined.
Future perspectives and conclusion
Given the wide range of effector molecules that use the
JAK/STAT pathway, the latter is increasingly an attractive
therapeutic target for a wide range of immune-mediated
diseases beyond RA. Further to those outlined in this
review, isolated reports of other immune-mediated condi-
tions treated with JAK inhibitors have been published and
will undoubtedly continue to appear in the literature
[105107]. Phase 1 and phase 2 clinical trials are
underway for SLE (NCT02535689, NCT03159936,
NCT03288324, NCT03134222, NCT02708095 and
NCT03285711), SSc (NCT03274076), SS (NCT03100942)
and DM (NCT03002649). The efficacy and safety profiles
of JAKinibs have not always corresponded with the ef-
fects predicted based on our understanding of the JAK/
STAT pathways and selectivity of these drugs. By corol-
lary, the relative risk between agents, and within their re-
spective dose ranges have not yet been established.
Long-term extension studies and rigorous post-market
surveillance will be key to defining the safety profile for
this category of drugs, particularly with the variety of
new and more selective JAK inhibitors likely to reach the
clinic in the next few years. The position of the JAKinibs in
the treatment algorithms for inflammatory arthritis and
other immune-mediated diseases remains to be defined.
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